Actelion Pharmaceuticals Ltd.
http://www1.actelion.com/en/index.page
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Actelion Pharmaceuticals Ltd.
Radiopharmaceutical Leader ITM Gets A Burst Of Energy – And Weighs Up Going Public
ITM is reaping benefits from long-term investment in radiopharmaceuticals manufacturing and is now looking to challenge its customer, Novartis, by bringing its first product to market.
Efficacy, Not Safety, Does For Merck KGaA’s BTK Inhibitor
Evobrutinib flunked its Phase III multiple sclerosis program not because of its known toxicity, but because it didn’t work.
Outlook 2024: Shaping A Medtech Environment Where Technology Leads The Way
Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.
Outlook 2024: Biopharma Embraces New Markets And New Tech
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
Company Information
- Other Names / Subsidiaries
-
- Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
- CoTherix, Inc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice